Tumour
Growth Control Group (CRUK) - Sir William Dunn School of Pathology
2014
Buehnemann, C., Li, S., Brandford-White,
H., Yu, H., Hogendoorn, P.C., Llombart-Bosch,
A., Picci, P., Noble, A., Hassan, A.B. Quantification
of the heterogeneity of prognostic cellular biomarkers in Ewing Sarcoma using
automated image and random survival forest analysis. (2014) PlosOne Sep 2014 9 (9) e107105.
2013
Hughes, J., Frago, S., Bühnemann,
C., Carter, E.J. and Hassan, A.B. Maternal transmission of a humanised Igf2r
allele results in an Igf2 dependent hypomorphic and non-viable growth phenotype. (2013) PlosOne e57270.
Barnes, D.J., Mumtaz, M., Hughes, J., Buehnemann, C., Hoppe,
H., Zhang, S., Prince, S.N., Taylor, S. and Hassan, A.B. IGF2 signalling
regulates the transcription module of the repressor REST in a specific and gene
dosage dependent manner in genetic models of ligand supply. (2013) in
preparation.
Frago, S., Strickland, M., Hughes,J., Williams,C., Garner,
L., Hoppe,H-J., Rezgui, D.,
Zaccheo,O.J., Prince,S.N, Crump,M.P. and Hassan, A.B. Directed evolution
of structurally selected IGF2R domain 11 binding loop residues generates an
IGF2 super-antagonist. (2013) in preparation.
Matheson, J., Bühnemann, C.,
Carter, E.J., Hughes, J., Hoppe, H-J., Hassan, A.B. Conditional disruption of Cdh1
(E-cadherin) modifies Apc loss of function in
intestinal adenoma to promote cell death and mesenchymal transition. (2013) in
preparation.
2012
Williams, C., Hoppe, H., Rezgui,
D., Strickland, M., Frago, S., Forbes, B., Gutzner,
F., Ellis, R.Z., Wattana-Amorn, P., Prince, S.N., Zaccheo, O.J., Jones, E.Y., Crump, M.C. and Hassan, A.B. An
exon splice enhancer primes IGF2:IGF2R binding site for structure and
functional evolution. (2012) Science 338; 1209-13.
van Maldegem, A.M., Bhosale, A, Gelderblom, H.J, Hogendoorn, P.C., Hassan, A.B. Comprehensive analysis of
published phase I/II clinical trials between 1990-2010 in osteosarcoma and
Ewing sarcoma confirms limited outcomes and need for translational investment. Clin Sarcoma Res. (2012) Jan 27;2(1):5.
van Maldegem, A.M., Hogendoorn, P.C., Hassan, A.B. The clinical use of
biomarkers as prognostic factors in Ewing sarcoma. Clin
Sarcoma Res. (2012) Feb 8;2(1):7.
2011
Li, P., Cavallero, S., Gu, Y., Chen, T.H., Hughes, J.,
Hassan, A.B., Brüning, J.C., Pashmforoush,
M., Sucov, H.M. IGF signaling
directs ventricular cardiomyocyte proliferation
during embryonic heart development. (2011) Development. 138:1795-805.
Church, D., Carter, E., Phillips, B., Stuckey, D., Buffa,
F., Manek, S., Clarke, K., Harris, A.L., Hassan,
A.B. Igf2 dependency of Pten (+/-)
developmental and tumour phenotypes in the mouse. (2011) Oncogene, 31:
3635-46.
Haley, V.L., Barnes, D.J., Graham, C.F., Sandovici,
I., Constancia, M. and Hassan, A.B. Synergistic and
dependent genetic interactions between Igf2 and p53 during embryonic and tumour
development, (2011) EMBO Molecular Medicine 4: 705-18.
2010
Jeyaratnaganthan N., Hojlund, K., Kroustrup, J.P., Larsen, J.F., Bjerre,
M., Levin, K., Beck-Nielson, H., Frago, S., Hassan, A.B., Flyvbjerg,
A., Frystyk, J. Circulating levels of
insulin-like growth factor II/ Mannose-6-phosphate receptor in obesity and type
2 diabetes. Growth Horm IGF Res. (2010)
20(3):185-91.
Casali, P.G., Blay, J.Y.; ESMO/
CONTICANET/ EUROBONET Consensus Panel of experts. Hassan, A.B. and 43
others. Gastrointestinal stromal tumours: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow up. (2010) Annals of
Oncology 21;Suppl 5:v98-102.
Hogendoorn, P.C.; ESMO/EuroBoNeT working
Group, Athanasou, N., Bielack, S., De Alava, E., Tos, A.P., Ferrari, S., Gelderblom,
H., Grimer, R., Hall, K.S., Hassan, A.B., Hogendoorn, P.C., Jurgens, H., Paulussen, M., Rozeman, L., Taminiau, A.H., Whelan, J., Vanel,
D. Bone Sarcomas: ESMO Clinical Practice Guidelines for diagnosis,
treatment, and follow-up. (2010) Annals of Oncology 21; Suppl 5:v204-13.
Casali, P.G., Blay, J.Y.; ESMO/
CONTICANET/ EUROBONET Consensus Panel of experts. Hassan, A.B. and 43
others. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. (2010) Annals of Oncology 21;Suppl 5:v198-203.
2009
Rezgui, D., Williams, C., Savage, S.A., Prince, S.N., Zaccheo, O.J., Jones, E.Y., Crump, M.P. and Hassan, A.B.
Structure and function of the human Gly1619Arg polymorphism of M6P/IGF2R domain
11 implicated in IGF2 dependent growth. J Mol
Endocrinology, (2009) 42:341-56.
2008
Brown, J., Delaine, C., Zaccheo,
O., Siebold, C., Gilbert, R., van Boxel,
G., Denley, A., Wallace, J., Hassan, A.B., Forbes, B.,
and Jones E.Y. Structure and functional analysis of the IGF-II/IGF2R
interaction. (2008) EMBO J 27:265-76.
Varey, A.H., Rennel, E.S., Qiu, Y., Bevan, H.S., Perrin, R.M., Raffy,
S., Dixon, A.R., Paraskeva, C., Zaccheo,
O., Hassan, A.B., Harper, S.J., Bates, D.O. VEGF(165)b, an antiangiogenic
VEGF-A isoform, binds and inhibits bevacizumab
treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for
therapy. Br J Cancer. (2008), 98, 1366-79.
Stocken, D.D., Hassan, A.B., Altman, D. et al. Modelling
prognostic factors in advanced pancreatic cancer. Br J Cancer
(2008). 99, 883-93.